AIP
BMRN icon

Arrowpoint Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arrowpoint Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Sell
27,041
-21,678
-44% -$1.19M 0.34% 44
2026
Q1 		$2.75M Buy
+48,719
New +$2.84M 2.45% 10

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Arrowpoint Investment Partners's BMRN Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 44% in Q2 2026, selling an estimated $1.19M and leaving 27,041 shares worth $1.55M. The position accounts for 0.34% of the portfolio, ranked #44.

Arrowpoint Investment Partners first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.75M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Arrowpoint Investment Partners held 27,041 shares of BioMarin Pharmaceuticals worth $1.55M as of Q2 2026.
  • Arrowpoint Investment Partners sold 21,678 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
  • BioMarin Pharmaceuticals made up 0.34% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #44 holding.
  • Arrowpoint Investment Partners first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Arrowpoint Investment Partners's BioMarin Pharmaceuticals position peaked at $2.75M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.